Manufacturing, Parenterals and Injectables

Microdermics will focus on product development and clinical activities of new drug delivery methods, while Vetter’s primary role will be in the fill and finish aspect.

The unique structures of fusion proteins lead to expression, heterogeneity, and stability issues.

Baxter will acquire Claris Injectables Limited, adding additional generic injectable capabilities to the company’s porfolio.

Second-generation needle-free injection systems will make parenteral drug administration more convenient, efficient, and safe.

The correlation between limulus amebocyte lysate (LAL) assay and rabbit pyrogen test (RPT) targeting recombinant human epidermal growth factor (rhEGF) as active molecule was assessed.

A Q&A with SCHOTT Pharmaceutical Systems and West Pharmaceutical Services

NIBRT's Ray O'Connor provides an overview of aseptic processing.

The sugars used to stabilize lyophilized proteins often have not been subjected to appropriate cGMP standards.